RxDoctor Payments Data

Ashleigh Hickerson, APRN

Acute Care · Madisonville, KYNPI 1063963676

Payments from drug & device makers

$1,036in general payments, 2019–2025

Across 35 payments — averaging $29.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avadel CNS Pharmaceuticals, LLC$267
  • Jazz Pharmaceuticals Inc.$229
  • Inspire Medical Systems, Inc.$187
  • Harmony Biosciences LLC$146
  • Axsome Therapeutics, Inc.$86
  • Lilly USA, LLC$36
  • plus $84 from 4 others

What the payments were for

  • Consulting fees$35034%
  • Food & beverage$68666%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,036 in reported general payments places this provider in the 70th percentile of 319 acute care providers in Kentucky.

See all acute care providers in Kentucky

Medicare billing

Part B allowed, 2024
$26,739
Medicare patients
285
Services billed
383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QuviviqDaridorexant Hcl11$5,347
Doxepin Hcl12$1,549
Modafinil14$761
Ropinirole Hcl69$704
Trazodone Hcl56$302
Mirtazapine15$229
Fluticasone Propionate12$129
Zolpidem Tartrate19$125
Gabapentin42$123
Quetiapine Fumarate11$118
Temazepam13$106
Tramadol Hcl12$34

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Idorsia Pharmaceuticals US IncQuviviq$35$5,34711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 319 acute care providers in Kentucky.

Other acute care in Madisonville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →